---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-24-003187"
form_type: "8-K"
ticker: "ZOMDF"
cik: "0001684144"
company_name: "Zomedica Corp."
filed_at: "2024-03-15T23:59:59+00:00"
generated_at: "2026-06-04T17:27:20.059720+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Zomedica continues NYSE American listing dialogue after shareholder rejection of reverse split

## Summary
- Received NYSE American deficiency letter Sept 2023 for 30-day avg share price below $0.20 per Section 1003(f)(v).
- Shareholders rejected proposed 80:1 reverse stock split at Feb 28, 2024 special meeting; 67.7% majority required.
- Shares remain listed; exchange will monitor price and further deterioration could trigger delisting.
- CEO Larry Heaton cites progress and opportunities to positively impact share price.

## SEC filing metadata
- accession: 0001654954-24-003187
- form_type: 8-K
- ticker: ZOMDF
- cik: 0001684144
- company_name: Zomedica Corp.
- filed_at: 2024-03-15T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1684144/000165495424003187/0001654954-24-003187-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1684144/000165495424003187/zom_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-24-003187
- JSON: https://secwatch.observer/filing/0001654954-24-003187.json
- Plain text: https://secwatch.observer/filing/0001654954-24-003187.txt

## Key facts
- Listing & Compliance Notices
  Zomedica Corp. received a nyse_american deficiency notice notice regarding minimum bid price (rules 1003(f)(v)).
  - Exchange: nyse american
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 1003(f)(v)
  source text: March 13, 2024, Zomedica Corp. (the “Company”) announced that it was continuing its dialogue with the NYSE American LLC (the “NYSE American”) regarding next steps associated with the deficiency letter (the “Letter”) the Company received from NYSE American on September 12, 2023. As reported in a prior Form 8-K, the Letter indicated that the Company was not in compliance with the NYSE American continued listing standards set forth in Section 1003(f)(v) of the NYSE American Company Guide (the “Company Guide”) because the Company’s common shares were trading for a substantial period of time at a l
  evidence_url: https://www.sec.gov/Archives/edgar/data/1684144/000165495424003187/0001654954-24-003187-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.